Cancer Research UK tests first of its kind vaccine to treat lung cancer

AST-VAC2 is a vaccine developed against non-small cell lung cancer (NSCLC). It mainly composes of an immunotherapy derived from a standardized human embryonic stem cell line, enabling AST-VAC2 engineered dendritic cells to produce protein telomerase.

The vaccine has moved into phase 1 clinical trials, under the collaboration agreement between Cancer Research UK and Asterias Biotherapeutics Inc.